CCI-001 for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new drug, CCI-001, which targets a protein needed for cell division. It aims to find the safe dose and see how well it works in patients with various advanced cancers.
Will I have to stop taking my current medications?
The trial requires that you stop taking any investigational agents, chemotherapy, immunotherapy, radiotherapy, or molecular targeted agents at least 28 days before enrolling. If you are taking warfarin, you will need to stop, but low-dose or therapeutic heparin is allowed.
Who Is on the Research Team?
Jennifer Spratlin, MD
Principal Investigator
Alberta Health Services, University of Alberta
Are You a Good Fit for This Trial?
Adults with certain types of recurrent or metastatic solid tumors, who have tried other treatments without success or for whom no standard treatment exists. They must be in good health otherwise, with normal organ and marrow function, and not currently receiving other cancer therapies. Women can't be pregnant or nursing, and all participants must agree to use contraception.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
CCI-001 is administered at escalating doses to determine the maximum tolerated dose
Dose Expansion
Patients with specific tumour types are treated at the recommended dose determined during dose escalation
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- CCI-001
Find a Clinic Near You
Who Is Running the Clinical Trial?
PharmaMatrix Holdings Ltd
Lead Sponsor
University of Alberta
Collaborator